27340777|t|Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer
27340777|a|The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal / triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4 / PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype.
27340777	0	10	Activation	T052	C1879547
27340777	18	39	orphan receptor GPR55	T116,T192	C2002138
27340777	43	67	lysophosphatidylinositol	T109,T123	C0065391
27340777	68	76	promotes	T052	C0033414
27340777	77	87	metastasis	T191	C0027627
27340777	91	120	triple-negative breast cancer	T191	C3539878
27340777	125	158	orphan G protein-coupled receptor	T116,T192	C0682972
27340777	159	164	GPR55	T116,T192	C2002138
27340777	174	182	directly	T080	C1947931
27340777	186	196	indirectly	T080	C0439852
27340777	197	204	related	T080	C0439849
27340777	214	225	alterations	T078	C1515926
27340777	237	246	malignant	T080	C0205282
27340777	247	253	growth	T040	C0018270
27340777	255	267	uncontrolled	T080	C0205318
27340777	275	293	cell proliferation	T043	C0596290
27340777	295	317	sustained angiogenesis	T042	C0302600
27340777	330	343	cell adhesion	T043	C0007577
27340777	348	357	migration	T067	C1254366
27340777	368	374	little	T081	C0700321
27340777	378	383	known	T080	C0205309
27340777	394	405	involvement	T169	C1314939
27340777	414	422	receptor	T116,T192	C0597357
27340777	426	436	metastasis	T191	C0027627
27340777	457	465	elevated	T080	C3163633
27340777	466	482	GPR55 expression	T045	C0597360
27340777	486	491	human	T016	C0086418
27340777	492	498	tumors	T191	C0027651
27340777	502	517	associated with	T080	C0332281
27340777	522	538	aggressive basal	T191	C0027671
27340777	541	570	triple-negative breast cancer	T191	C3539878
27340777	571	581	population	T098	C1257890
27340777	583	601	higher probability	T081	C0033204
27340777	613	623	metastases	T191	C0027627
27340777	639	643	poor	T080	C2700379
27340777	644	651	patient	T101	C0030705
27340777	652	661	prognosis	T058	C0033325
27340777	663	673	Activation	T052	C1879547
27340777	677	682	GPR55	T116,T192	C2002138
27340777	699	709	endogenous	T169	C0205227
27340777	710	716	ligand	T103	C0023688
27340777	717	741	lysophosphatidylinositol	T109,T123	C0065391
27340777	750	762	pro-invasive	T080	C0205281
27340777	763	771	features	T080	C2348519
27340777	775	794	breast cancer cells	T025	C1512505
27340777	800	808	in vitro	T080	C1533691
27340777	813	820	in vivo	T082	C1515655
27340777	841	847	effect	T080	C1280500
27340777	851	862	elicited by	T080	C0449265
27340777	863	871	coupling	T169	C1948027
27340777	875	904	Gq/11 heterotrimeric proteins	T116,T123	C2975447
27340777	913	923	subsequent	T079	C0332282
27340777	924	934	activation	T052	C1879547
27340777	944	947	ERK	T116,T126	C0600388
27340777	956	981	transcription factor ETV4	T116,T123	C1333479
27340777	984	988	PEA3	T116,T123	C0084827
27340777	990	998	Together	T080	C1883357
27340777	1006	1010	data	T078	C1511726
27340777	1021	1026	GPR55	T116,T192	C2002138
27340777	1027	1035	promotes	T052	C0033414
27340777	1036	1049	breast cancer	T191	C0678222
27340777	1050	1060	metastasis	T191	C0027627
27340777	1066	1074	supports	T077	C1521721
27340777	1096	1111	orphan receptor	T116,T192	C0597357
27340777	1129	1132	new	T080	C0205314
27340777	1133	1144	therapeutic	T169	C0302350
27340777	1145	1151	target	T169	C1521840
27340777	1156	1165	potential	T080	C3245505
27340777	1166	1175	biomarker	T201	C0005516
27340777	1190	1224	aggressive triple-negative subtype	T185	C1519691